Publication | Closed Access

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunologyClinical TrialsHematologyImmune Checkpoint InhibitorObinutuzumab Versus ChlorambucilPharmacotherapyFollow-up ResultsImmunotherapyOncologyRadiation OncologyAdult T-cell Leukemia-lymphomaCancer ResearchHealth Sciences